Qiagen N.V. Common Shares (QGEN) closed at $46.55 on October 19, 2026, up 0.9% from the previous close, on volume of 2,065,602 shares (30-day average 1,938,789).
Data as of October 19, 2026.
19-Oct-2026
UBS Releases a Hold Rating on Qiagen (QGEN)
TipRanks (Mon, 19-Oct 9:35 AM ET)
BlackRock Discloses Significant Stake in Qiagen
TipRanks (Fri, 16-Oct 4:37 PM ET)
QIAGEN Spotlights Tuberculosis Funding Risk as QuantiFERON-TB Tops 160 Million Tests Sold
Market Chameleon (Wed, 14-Oct 3:08 AM ET)
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
Business Wire (Tue, 13-Oct 4:05 PM ET)
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
Business Wire (Tue, 6-Oct 4:05 PM ET)
Business Wire (Mon, 28-Sep 1:30 AM ET)
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
Business Wire (Thu, 24-Sep 4:05 PM ET)
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
Business Wire (Fri, 18-Sep 4:05 PM ET)
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
PRNewswire (Fri, 28-Aug 2:39 PM ET)
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
Business Wire (Thu, 27-Aug 4:05 PM ET)
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
Qiagen N.V. Common Shares trades on the NYSE stock market under the symbol QGEN.
As of October 19, 2026, QGEN stock price climbed to $46.55 with 2,065,602 million shares trading.
QGEN has a beta of 0.48, meaning it tends to be less sensitive to market movements. QGEN has a correlation of 0.03 to the broad based SPY ETF.
QGEN has a market cap of $9.59 billion. This is considered a Mid Cap stock.
Last quarter Qiagen N.V. Common Shares reported $535 million in Revenue and $.62 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.02.
In the last 3 years, QGEN traded as high as $57.82 and as low as $32.53.
The top ETF exchange traded funds that QGEN belongs to (by Net Assets): IWR, IWD, FXH, IWS, FMDE.
QGEN has underperformed the market in the last year with a return of +2.2%, while SPY returned +17.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in QGEN shares. However, QGEN has outperformed the market in the last 3 month and 2 week periods, returning +12.1% and +4.0%, while SPY returned +2.4% and -0.4%, respectively. This indicates QGEN has been having a stronger performance recently.
QGEN support price is $45.14 and resistance is $47.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QGEN shares will trade within this expected range on the day.
